Antibodies against C1q in patients with systemic lupus erythematosus.
The first component of the classical pathway of complement (C1q) is considered to be involved in the pathogenesis of systemic lupus erythematosus (SLE). This view is based on the observation that a substantial number of patients with SLE develop hypocomplementemia with depletion of the classical pathway components, and C1q has been shown to play an important role in the clearance of immune complexes and apoptotic bodies. In addition, homozygous C1q deficiency is the strongest disease susceptibility gene for the development of SLE that has been characterised in humans. However, most SLE patients have no primary complement deficiency. Hypocomplementemia in SLE patients is a secondary event and often associated with antibodies against C1q (anti-C1q). Although anti-C1q have been found in a number of distinct autoimmune disorders, they are best described in patients with SLE where they strongly correlate with renal flares. Current data suggest that the occurrence of anti-C1q in SLE patients is necessary but not sufficient for the development of proliferative lupus nephritis, suggesting an interference with the normal function of the complement system.
Trendelenburg
Marten
M
Medical Clinic B, University Hospital Basel, Petersgraben 4, Basel 4031, Switzerland. marten.trendelenburg@unibas.ch
D001323:Autoantibodies / Q000097:blood* / Q000266:history; D015922:Complement C1q / Q000096:biosynthesis / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D049673:History, 20th Century; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000209:etiology / Q000276:immunology*; D008181:Lupus Nephritis / Q000276:immunology; D018448:Models, Immunological
D001323:Autoantibodies; D015922:Complement C1q